ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Omeros Corporation

Omeros Corporation (OMER)

6.48
2.29
( 54.65% )
Updated: 12:07:09

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
6.48
Bid
6.45
Ask
6.50
Volume
11,042,903
4.41 Day's Range 7.51
1.375 52 Week Range 7.51
Market Cap
Previous Close
4.19
Open
4.42
Last Trade
18
@
6.5
Last Trade Time
12:07:10
Financial Volume
$ 67,950,737
VWAP
6.1533
Average Volume (3m)
234,155
Shares Outstanding
57,946,859
Dividend Yield
-
PE Ratio
-3.48
Earnings Per Share (EPS)
-2.03
Revenue
-
Net Profit
-117.81M

About Omeros Corporation

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Tumwater, Washington, USA
Founded
-
Omeros Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OMER. The last closing price for Omeros was $4.19. Over the last year, Omeros shares have traded in a share price range of $ 1.375 to $ 7.51.

Omeros currently has 57,946,859 shares outstanding. The market capitalization of Omeros is $242.80 million. Omeros has a price to earnings ratio (PE ratio) of -3.48.

Omeros (OMER) Options Flow Summary

Overall Flow

Bullish

Net Premium

92k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

OMER Latest News

Omeros Corporation Reports Third Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market...

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug...

Omeros Corporation Reports Second Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.9543.04635761594.537.514.1753177754.30819482CS
42.3657.28155339814.127.514.0052383164.27127186CS
122.2252.11267605634.267.513.542341554.03774696CS
262.6870.52631578953.87.513.00013180514.15769077CS
525.043501.447.511.3754445573.62214189CS
156-1.73-21.0718635818.218.60.926842044.27054672CS
260-7.41-53.347732181413.8925.490.927359518.55840908CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MTEMMolecular Templates Inc
$ 0.759117
(135.68%)
213.26M
GORVLazydays Holdings Inc
$ 1.57
(70.65%)
3.16M
OMEROmeros Corporation
$ 6.44
(53.70%)
10.98M
AGFYAgrify Corporation
$ 15.20
(45.73%)
557.58k
QUBTQuantum Computing Inc
$ 3.775
(41.92%)
138.03M
SOWGSow Good Inc
$ 4.54
(-53.72%)
1.54M
NVCTNuvectis Pharma Inc
$ 6.3297
(-40.68%)
1.32M
TRNRInteractive Strength Inc
$ 3.7327
(-35.97%)
1.1M
OPRXOptimizeRx Corporation
$ 4.12
(-33.01%)
1.21M
JTAIJet AI Inc
$ 5.62
(-30.79%)
312.64k
ELABElevai Labs Inc
$ 0.027699
(12.14%)
1.51B
XTIAXTI Aerospace Inc
$ 0.0633
(10.66%)
313.86M
MTEMMolecular Templates Inc
$ 0.751725
(133.38%)
213.5M
SVMHSRIVARU Holding Ltd
$ 0.0274
(13.22%)
211.03M
QUBTQuantum Computing Inc
$ 3.77
(41.73%)
138.05M

OMER Discussion

View Posts
TrendTrade2016 TrendTrade2016 2 hours ago
OMER MONSTER PLAY OF THE DAY
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
OMER new 52=week low
Then bounce
πŸ‘οΈ0
shurtha2000 shurtha2000 1 year ago
$341M cash and $12M recievables
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Gap filled 6s 7s next top
πŸ‘οΈ0
Roadtojourney Roadtojourney 2 years ago
With the type of news this should have been above 5 not sure whats wrong here?
πŸ‘οΈ0
starkd748 starkd748 2 years ago
3.20 gap must fill now
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
OMER $200M PAYMENT
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$OMER: She back on fire now............ sheeeshhhhhhhhhhhhhh


Go baby goooooooooo.......... $3 breaker upside




GO $OMER
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Weeeeeeee
πŸ‘οΈ0
starkd748 starkd748 2 years ago
We get some 5s I'm backing up the truck
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Was a good trade but it's been done since 7s
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Weeeeee
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Weeeeeeeeeeeee
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Yesss
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Looking good
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Weeeeee
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Yesss
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Bounced off the low 3s time to load
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Maybe an A B C ... 2.17 might coming
πŸ‘οΈ0
starkd748 starkd748 2 years ago
Not ready yet
πŸ‘οΈ0
starkd748 starkd748 2 years ago
I like this at a certain fib level hehehe
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Great day here! $OMER
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Breaking out!
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Looking good here. Steady climb
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Looking good here. Steady climb
πŸ‘οΈ0
Scott 75 Scott 75 3 years ago
Wow! Thanks for sharing. I can't believe with all that going for it and the price is so beaten down.
πŸ‘οΈ0
Nefyn Nefyn 3 years ago
So what happens to OMER…a public company with tons of cash and no business operations?
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
Bahhh Bahhh

gonna do this all day long
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
another round for the apes Lets GO !!
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
Glad I'm just a robot no emotions needed
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
Fk with BB My new addiction
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
IN now I'm gonna tick flip this POS to death
πŸ‘οΈ0
JackAskSlap JackAskSlap 3 years ago
Trying for the baseline
no holds barred..
πŸ‘οΈ0
Jess070283 Jess070283 3 years ago
Load it up!$$$
πŸ‘οΈ0
TheGreenReaper TheGreenReaper 3 years ago
OMER$$$$
πŸ‘οΈ0
Golden Cross Golden Cross 3 years ago
$14 Targeting
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
59M trading float. Huge news out >
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Shorts feeling the heat!!!!! >
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
>>>>> GANGBUSTERS <<<<< $$$$$

OMER
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
OMER > That is a sweet revenue deal. OMER heading to $20.00+
$125 million upfront payment and $200 million on achievement of commercial milestone
Royalties of 50% on U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million milestone, after which royalties adjust to 30% of U.S. net sales
Royalties of 15% on ex-U.S. net sales
OMIDRIA to become a premier product in Rayner’s ophthalmology franchise
In addition to acquiring the OMIDRIA commercial organization, including the current OMIDRIA sales force, Rayner plans to further expand its U.S. and ex-U.S. sales forces
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/omeros-OMER/stock-news/86711139/omeros-announces-agreement-to-sell-omidria-franch
πŸ‘οΈ0
Frankestin Frankestin 3 years ago
Here are the 5!
Very interesting if it goes under!
I would be tempted to open the position now!
πŸ‘οΈ0
Frankestin Frankestin 3 years ago
Someone says 5 ... will it get there?
I would like to enter but of course they spend a lot on research and development... and for sell
πŸ‘οΈ0
Frankestin Frankestin 3 years ago
ooOOoo
I take a handful these days!
πŸ‘οΈ0
Termite7 Termite7 3 years ago
Buying opportunity???
πŸ‘οΈ0
frugalNorwegian frugalNorwegian 3 years ago
I created a page on my site talking about OMER. Let me know if I am missing any nuggets. Thanks.

https://frugalnorwegian.com/omer

Summary: This company is a prime candidate for a buyout if FDA approval is given.
πŸ‘οΈ0
Dr_Thorfin Dr_Thorfin 3 years ago
If one is worried about fda's delay, Check out @alanrobertross message on StockTwits http://stocktwits.com/alanrobertross/message/333077805
πŸ‘οΈ0
umiak umiak 4 years ago
Tute ownership up to 78% been hovering around 50% for years. 20% short
πŸ‘οΈ0
umiak umiak 4 years ago
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

The FDA has set the Prescription Drug User Fee Act action date on July 17.
πŸ‘οΈ0
umiak umiak 4 years ago
Have you looked at NLST? Short story:

*google signed a NDA with NLST to use their seminal technology
*google was bad even lied to court
*they lost their appeal
*google let date to file with scotus pass
*now one way or another they must pay
*one way to pay--google's case and settlement with ADT(eye opening)
*another way to pay-- Centripetal v Cisco (cisco was bad for 3 yrs
google is on the hook for 11 yrs)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160597164
*estimate to file to lift stay Q1 2021
*bought dips as low as .48 keep adding
*yahoo board and ihub board are bullish
lots of speculation but also good info.
*there are active cases with other companies Sk-hynic recently lost
on 2 parts of patent 907
*scheduled markman for infringement of (NLST)patents 218 and 595 3/9/2021
trial, if defendants choose, 12/2021
*it is a popping year for NLST they have been chasing google in court for 11 yrs, google will have to settle.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock